This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc (TDOC) Introduces Telemedicine Services in Canada
by Zacks Equity Research
Teladoc (TDOC) introduces Teladoc Telemedicine Services for Canadians. The new offering will enable them to enjoy convenient healthcare services.
Teladoc to Acquire MedecinDirect, Expand Overseas Business
by Zacks Equity Research
Teladoc's (TDOC) acquisition of MedecinDirect will aid it in enhancing presence in expanding virtual care market in France.
Teladoc (TDOC) Q4 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
Teladoc (TDOC) reports lower losses supported by an increase in revenues partly offset by a rise in expenses.
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.
Teladoc (TDOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc Expands Services with Virtual Back Pain Treatment
by Zacks Equity Research
Teladoc's (TDOC) new addition of virtual back pain treatment will broaden its suite of products and services.
What's in Store for Teladoc in 2019, After a Strong 2018?
by Zacks Equity Research
Teladoc (TDOC) should continue to gain from increasing demand for its services and global expansion.
Which Stock to Emulate HCA Healthcare (HCA) Success in 2019?
by Zacks Equity Research
While HCA Healthcare (HCA) has been a runaway winner this year, other companies by virtue of strong operating fundamentals are poised for growth in 2019.
Teladoc (TDOC) Surges 64% in a Year: Can the Rally Continue?
by Zacks Equity Research
Teladoc (TDOC) is poised to grow on accelerating demand for its telehealth services.
Teladoc (TDOC) Q3 Loss Lower Than Estimates, Revenues Beat
by Zacks Equity Research
Teladoc's (TDOC) Q3 results show lower losses, revenues gain from increase in membership and patient visits.
Teladoc (TDOC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 5.56% and 0.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Advance Medical Buyout Aid Teladoc (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc (TDOC) is expected to chip in with a solid top-line contribution from its acquisition of Advance Medical in Q3.
Teladoc (TDOC) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Teladoc (TDOC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc Leads Telehealth Thanks to its Virtual Care Solution
by Zacks Equity Research
Teladoc's (TDOC) vast product portfolio, client base, tie-ups and acquisitions make it a leader in the telehealth industry.
Why Is Teladoc (TDOC) Up 16.4% Since Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc (TDOC) Up 26% in 22 Days, Will Upside Continue?
by Zacks Equity Research
Teladoc (TDOC) shares gain on strong operating performance in second quarter.
Teladoc (TDOC) Hits 52-Week High, Will the Rally Continue?
by Zacks Equity Research
Strong second-quarter earnings performance and favorable guidance pulled up the stock of Teladoc (TDOC).
Teladoc (TDOC) Incurs Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Teladoc (TDOC) incurs loss owing to high expenses, partly offset by revenue growth.
Teladoc (TDOC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 2.63% and 2.76%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Revenue Growth Drive Teladoc (TDOC) Q2 Earnings Higher?
by Zacks Equity Research
Teladoc (TDOC) Q2 earnings to gain from increased patient visits and subscription fees.
Teladoc (TDOC) Buys Advance Medical to Boost Global Presence
by Zacks Equity Research
Teladoc's (TDOC) purchase of Advance Medical is in sync with its strategy to lap up complementary businesses and expedite growth.
Why Is Teladoc (TDOC) Up 19% Since Its Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Teladoc Reaches a 52 Week High, Stock Up 22%
by Zacks Equity Research
Teladoc's (TDOC) robust results and a favorable guidance increase the stock price.
Teladoc (TDOC) Loss Lower Than Expected, '18 View Intact
by Zacks Equity Research
Teladoc (TDOC) Q1 results showed an increase in revenues led by higher visits and membership.
Humana (HUM) Q1 Earnings to Benefit From Medicare Business
by Zacks Equity Research
Humana (HUM) Q1 earnings should see upside from higher revenues in Retail segment, but investments may increase total expenses.